The results of this study elucidate the role of Gly482Ser polymorphism in PPARGC1A and may provide useful information for the design of PPARGC1A variant-based therapeutic strategies against CAD, NAFLD, T2DM, obesity, hypertension, and metabolic diseases. Here, PPARGC1A is linked to metabolic disease.